NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Br

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Brandon Owens ,Kate Mcneil ,Pierre Louis Germain ,Linkedin ,French Financial Markets Authority Autorit ,Communications Department ,Twitter ,Investor Relations Department ,Nasdaq ,Exchange Commission ,Pharmaengine Inc ,Euronext ,American Society ,Regulatory News ,Clinical Oncology ,Laurent Levy ,Comprehensive Approach ,Locally Advanced Head ,Neck Cancer Inclusive ,Concurrent Chemoradiation ,Locally Advanced ,Recurrent Head ,Neck Squamous Cell Carcinoma ,Neoadjuvant Setting ,Unresectable Rectal Cancer ,Private Securities Litigation Reform Act ,Annual Report ,French Financial Markets Authority ,Des March ,Half Year Financial Report ,